KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy is a key cancer treatment, with PD-L1 (programmed death-ligand 1) being a target in non-small cell lung cancer (NSCLC).
• The regulatory mechanisms and functions of PD-L1 in lung cancer remain incompletely understood.
• Understanding PD-L1 regulation is crucial for improving anti-cancer immune responses.

Purpose of the Study:

• To elucidate the regulatory mechanism of PD-L1 degradation in NSCLC.
• To investigate the role of KEAP1 (Kelch-like ECH-associated protein 1) in PD-L1 regulation and anti-cancer immunity.
• To evaluate the therapeutic potential of targeting the KEAP1-PD-L1 pathway in NSCLC.

Main Methods:

• Investigated KEAP1 as an E3 ligase for PD-L1 ubiquitination and degradation.
• Assessed the impact of KEAP1 overexpression on tumor growth and cytotoxic T-cell activation in vivo.
• Analyzed the combined effects of elevated KEAP1 expression and anti-PD-L1 immunotherapy.
• Correlated KEAP1 and PD-L1 expression levels with NSCLC patient prognosis.

Main Results:

• KEAP1 functions as an E3 ligase, promoting PD-L1 ubiquitination and subsequent degradation.
• Overexpression of KEAP1 suppressed tumor growth and enhanced cytotoxic T-cell activation in vivo.
• Combined KEAP1 elevation and anti-PD-L1 therapy demonstrated synergistic anti-tumor effects.
• KEAP1 and PD-L1 expression levels are significantly associated with NSCLC prognosis.

Conclusions:

• KEAP1 plays a critical role in regulating PD-L1 stability and thereby influences anti-cancer immunity in NSCLC.
• The KEAP1-PD-L1 signaling pathway is a key mechanism for NSCLC immune escape.
• KEAP1 agonists represent a promising therapeutic strategy to enhance anti-tumor immunity and improve the efficacy of immunotherapies in NSCLC.